On June 20, 2026, CureGene Pharmaceutical revealed that the initial participant has been effectively administered in the pivotal clinical trial of Evategrel (CG-0255) in the United States. Evategrel is a novel top-tier antiplatelet agent developed by the company. This signifies the initiation of a significant phase in the trial process.